Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis

BACKGROUND: Tixagevimab-cilgavimab is used for pre-exposure prophylaxis of COVID-19 in immunocompromised patients, though in vitro data has shown reduced neutralizing activity against SARS-CoV-2 Omicron subvariants. METHODS: We performed genomic sequencing of SARS-CoV-2 isolated from patients diagno...

Descripción completa

Detalles Bibliográficos
Autores principales: Ordaya, Eloy E., Vergidis, Paschalis, Razonable, Raymund R., Yao, Joseph D., Beam, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2023
Materias:
Paper from the 21st ESCV meeting
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9877152/
https://www.ncbi.nlm.nih.gov/pubmed/36731147
http://dx.doi.org/10.1016/j.jcv.2023.105382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9877152/
https://www.ncbi.nlm.nih.gov/pubmed/36731147
http://dx.doi.org/10.1016/j.jcv.2023.105382

Ejemplares similares